Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-cell Therapy, in US Adults with B-ALL
Key Points
Cytokine release syndrome and neurotoxicity lead to significant healthcare costs, impacting patient management.
The analysis identified average treatment costs exceeding $100,000 for incidents of CRS and ICANS post CAR T-cell therapy.
Observational analysis assessed healthcare expenditures in relation to treatment outcomes and adverse events.
Impacts and financial burdens from these syndromes highlight the need for improved cost management strategies.
Real-World Cost of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-cell Therapy, in US Adults with B-ALL | Synapse